NeurologyLive | Direct Access to Expert Insight in Neurology

Clinical Focus

Video Series

Publications

Current Issue

Disease Management on the Horizon in Alzheimer Disease

Sigma-1 Agonists Offer Combination Approach to Dementia Symptoms

Efforts to Cure SMA Follow Multiple Pathways

An interview with Marwan Sabbagh, MD

Disease Management on the Horizon in Alzheimer Disease

NeurologyLive spoke with the director of the Cleveland Clinic Lou Ruvo Center for Brain Health to learn why, despite hundreds of failed trials and therapies, there is growing excitement for what's to come.

Exome Panel Promising for Diagnosing Epilepsy, Pamrevlumab for Duchenne Muscular Dystrophy Receives Orphan Drug Designation, Riluzole NDA Accepted for ALS

Neurology News Network for the week of April 20, 2019.

pNF-H Has Potential As Biomarker of Spinal Muscular Atrophy Disease Activity

Infants with SMA—who have elevated pNF-H levels—experienced significant drops in pNF-H levels when treated with nusinersen (Spinraza, Biogen), suggestive of pNF-H’s potential as a biomarker of disease activity and treatment response.

Wolfgang Muhlhofer, MD, on the Duration of Therapeutic Coma As Treatment for Refractory Status Epilepticus

The Assistant Professor at the University of Alabama School of Medicine spoke about the results of a recent cohort study that found that a shorter, yet deeper therapeutic coma may be safer and more effective than the currently recommended therapeutic coma duration for refractory status epilepticus.

Early DOAC Therapy Linked to Reduced ICH Risk in AFib-Related Stroke

The study provides class 2A and Level B evidence that DOAC therapy started in a median of 5 days following ischemic stroke in patients with atrial fibrillation is beneficial compared with VKA therapy.

Ongoing Unmet Needs for Patients With Epilepsy

Pascal Sati, PhD: Validating the Central Vein Sign in Multiple Sclerosis Diagnosis

Using Stereo EEG to Evaluate Seizures